Skip to Main Content

Paper Details

EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.
J Clin Oncol
153
2020
Author NameAffiliation
David C SmithUniversity of Michigan ann arbor
Joshua M LangUniversity of Wisconsin Carbone Cancer Center
Elisabeth I HeathBarbara Ann Karmanos Cancer Institute, Wayne State University
David I QuinnUniversity of Southern California Norris Comprehensive Cancer Center
  • 1 - 4

Datasets

Release 1.2